Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients
Open Access
- 18 September 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00228
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic has impacted health care worldwide, with specific patient populations, such as those with diabetes, cardiovascular disease, and chronic lung disease, at higher risk of infection and others at higher risk of disease progression. Patients with decompensated cirrhosis fall into the latter category and are a unique group that require specific treatment and management decisions because they can develop acute-on-chronic liver failure. In liver transplant recipients, the atypical immunity profile due to immunosuppression protects against downstream inflammatory responses triggered by COVID-19. This exhaustive review discusses the outcomes associated with COVID-19 in patients with advanced cirrhosis and in liver transplant recipients. We focus on the immunopathogenesis of COVID-19, its correlation with the pathogenesis of advanced liver disease, and the effect of immunosuppression in liver transplant recipients to provide insight into the outcomes of this unique patient population.Keywords
This publication has 124 references indexed in Scilit:
- Liver immunology and its role in inflammation and homeostasisCellular & Molecular Immunology, 2016
- Immunology in the liver — from homeostasis to diseaseNature Reviews Gastroenterology & Hepatology, 2016
- Can paracetamol (acetaminophen) be administered to patients with liver impairment?British Journal of Clinical Pharmacology, 2015
- Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severityCytokine, 2015
- Inflammatory status in human hepatic cirrhosisWorld Journal of Gastroenterology, 2015
- Lactate Reduces Liver and Pancreatic Injury in Toll-Like Receptor– and Inflammasome-Mediated Inflammation via GPR81-Mediated Suppression of Innate ImmunityGastroenterology, 2014
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012
- Toxicity prediction of compounds from turmeric (Curcuma longa L)Food and Chemical Toxicology, 2010
- Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathwaysBiological Chemistry, 2009